Recent research have converged on the intersection of glucagon-like peptide-1|GIP|GCGR stimulant therapies and DA neurotransmission. While GIP stimulators are increasingly employed for addressing type 2 T2DM, their emerging impacts on motivation circuits, specifically influenced by DA pathways, a